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Abstract
Background: A nation-wide surveillance study was conducted in Greece in order to provide a
representative depiction of pneumococcal carriage in the pre-vaccination era and to evaluate
potential risk factors for carriage of resistant strains in healthy preschool children attending daycare
centers.
Methods: A study group was organized with the responsibility to collect nasopharyngeal samples
from children. Questionnaires provided demographic data, data on antibiotic consumption, family
and household data, and medical history data. Pneumococcal isolates were tested for their
susceptibility to various antimicrobial agents and resistant strains were serotyped.
Results: Between February and May 2004, from a total population of 2536 healthy children, a yield
of 746 pneumococci was isolated (carriage rate 29.41%). Resistance rates differed among
geographic regions. Recent antibiotic use in the last month was strongly associated with the
isolation of resistant pneumococci to a single or multiple antibiotics. Serotypes 19F, 14, 9V, 23F and
6B formed 70.6% of the total number of resistant strains serotyped.
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Conclusion: Recent antibiotic use is a significant risk factor for the colonization of otherwise
healthy children's nasopharynx by resistant strains of S pneumoniae. The heptavalent pneumococcal
conjugate vaccine could provide coverage for a significant proportion of resistant strains in the
Greek community. A combined strategy of vaccination and prudent antibiotic use could provide a
means for combating pneumococcal resistance.
Background
Streptococcus pneumoniae is the most commonly isolated
pathogen in community-acquired respiratory tract infec-
tions, being the causative agent of a variety of infections,
such as acute otitis media, sinusitis and pneumonia [1].
The development of antibiotic resistance in S pneumoniae
over the last two decades has raised a global concern [2],
an evolution generally attributed to an extensive con-
sumption of antibiotics [3].
The nasopharynx of preschool children is the ecological
niche of S pneumoniae [4]. Nasopharyngeal colonization is
a prerequisite for progression to pneumococcal disease
and an important source of horizontal spread in the com-
munity, especially in settings with high crowding index
[1]. Antibiotic-resistant pneumococci involve mostly only
a few serogroups in the majority of developed countries
(6, 9, 14, 19 and 23). The routine immunization with the
heptavalent pneumococcal conjugate vaccine has been
shown to decrease the incidence of vaccine-type antibi-
otic-resistant pneumococci both in invasive diseases;
nasopharyngeal colonization was also dramatically
decreased in vaccinated individuals and their contacts [5].
In Greece, surveillance studies addressing the issue of
resistance and serotype distribution in nasopharyngeal
isolates of Streptococcus pneumoniae have been conducted
in recent years [6,7]. Although these studies covered spe-
cific regions of the Greek territory, a rise in the frequency
of antibiotic-resistant pneumococci has been docu-
mented. Recently, another study [8] assessed at regional
level the impact of the heptavalent pneumococcal vacci-
nation on the nasopharyngeal carriage of penicillin-resist-
ant pneumococci among day-care attendees.
The heptavalent pneumococcal conjugate vaccine became
available in October 2004 and formed part of the national
immunization schedule in January 2006. Between Febru-
ary and May 2004 (pre-vaccination era), the present large-
scale study was conducted in Greece, through a multi-
center initiative task force, in order to provide for the first
time a nation-wide representative depiction of carriage of
pneumococcal strains isolated from the nasopharynx of
healthy preschool children, attending daycare centers and
kindergartens. Data on resistance rates and serotype distri-
bution at nation-wide level from this study were pub-
lished in correlation with data for clinical strains from
children and adults for the same period of time [9]. The
purpose of the present article is to identify and evaluate
risk factors for carriage of resistant pneumococcal strains
in this specific population in the pre-vaccination era.
Methods
Study group and study population
A study group of 12 hospitals was organized under the
coordination of the 4th Department of Internal Medicine
and the Infectious Diseases Laboratory of Athens Univer-
sity Medical School (see Acknowledgements section). The
research protocol was approved by the Ministries of
Health and Education and the Ethics Committees of all
cooperating hospitals. A network was formed consisting
of local teams with the responsibility to inform parents
and collect appropriately filled questionnaires, collect and
culture nasopharyngeal samples from the children, isolate
presumed pneumococcal strains, store and ship isolated
strains to the central laboratory (Laboratory for Infectious
Diseases and Antimicrobial Chemotherapy, 4th Dept of
Internal Medicine, Athens University School of Medicine,
University General Hospital ATTIKON). The single central
laboratory undertook the microbiological procedures and
the input of data from the questionnaires in a purpose-
structured database.
Questionnaires were distributed to the parents by the
local teams of doctors visiting the day-care centres 1–2
days before the sampling visit. On the sampling day, ques-
tionnaires were reviewed by the doctors' team. In the sec-
tion of recent antibiotic use, parents were asked to provide
generic or commercial names of all medications received
in the last month or trimester and the appropriate classifi-
cation was performed by the responsible doctors in the
sampling site. Questionnaires were signed by the parents,
were anonymous but labeled to match the respective sam-
ple per child, and consisted of three parts: a) demographic
data, i.e. age, gender, name of daycare center, area and
prefecture; b) data on antibiotic consumption in the last
month and in the last trimester preceding the sampling,
including: number of antibiotic courses, name of antimi-
crobial and reason for its prescription, mode of supply
(over-the-counter or by prescription), c) family and
household data, i.e. parents working in health care,
number of siblings <8 years of age, and d) co morbidities
and past medical history data: admission to hospital in
the last year, history of « respiratory tract infections », oti-BMC Infectious Diseases 2009, 9:120 http://www.biomedcentral.com/1471-2334/9/120
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tis media history in the previous year and steroid use.
Children without signed questionnaires by the parents
were excluded from sampling, as well as those receiving
antibiotics for active infection. Samples without appropri-
ately filled questionnaires were microbiologically proc-
essed but were excluded from risk factor analysis.
Sampling procedure and microbiological process of 
pneumococcal strains
The period of sampling started February 2004 and lasted
until the end of May 2004. Carriage samples were col-
lected per nasally with sterile swabs on flexible alumin-
ium wire (Medical Wire & Equipment, Corsham, UK).
Swabs were immediately plated on Columbia agar plates
(Becton Dickinson, Sparks, MD) supplemented with 5%
defibrinated horse blood and packed in 5% CO2 Gas Pak
Pouches (Becton Dickinson).
Streptococcus pneumoniae isolates were identified by
standard microbiological procedures. Susceptibility test-
ing was performed with the E-test methodology (AB Bio-
disk, Solna, Sweden) for penicillin(PG), cefuroxime
(CXM), ceftriaxone(CTX), erythromycin(ERY), trimetho-
prim/sulfamethoxazole (COT), tetracycline (TET), moxi-
floxacin, levofloxacin and ciprofloxacin (CIP). Strains
displaying resistance were serotyped by the Quellung reac-
tion using the 12 pooled antisera Pneumotest panel and
selected factor sera (Statens Serum Institut, Copenhagen,
Denmark). Methodology of sampling, isolation, identifi-
cation and serotyping of pneumococcal strains, as well as
susceptibility testing is mentioned elsewhere in detail [9].
Definitions of terms
Clinical and Laboratory Standards Institute methodology
and breakpoints for non-susceptibility and resistance were
used for all antibiotics [10], except for ciprofloxacin. For
ciprofloxacin, the epidemiological cut-off of 2 mg/L was
used as an indicator of resistance, according to the Euro-
pean Committee on Antimicrobial Susceptibility Testing
(EUCAST) 2006 recommendations [11]. Strains with an
MIC value higher than the susceptibility breakpoint were
characterized as "non-susceptible", i.e. intermediate and
fully resistant strains. Combined resistance was defined as
resistance to two different classes of antibiotics (e.g. peni-
cillin and erythromycin) irrespective of other classes. Mul-
tiple resistance (or  multi-resistance) was defined as
resistance to 3 or more antibiotics of different classes [2].
Statistical analysis
Potential risk factors for carriage of pneumococci and in
particular of resistant pneumococcal strains were identi-
fied by univariate analysis. Antibiotic use was further ana-
lyzed using multivariate logistic regression analysis,
controlling for variables that were significant in the uni-
variate analysis and those that could correlate with an
increased risk of carriage of resistant/non-susceptible
strains from a clinical point of view. The following param-
eters were entered for analysis in the multivariate logistic
regression models: age, gender, location of day care center
or kindergarten, number of young siblings in the house-
hold with age <8 years, hospitalization, recent use of anti-
biotic by subject, steroid use, history of otitis media and
history of respiratory tract infections. A P value of = 0.05
was considered to be statistically significant.
Results
Study population and demographics
Between February and May 2004, consecutive nasopha-
ryngeal swabs and questionnaires were collected from
2595 healthy children (median age ± S.D. 4.3 ± 1.1 years,
male: female ratio 1:1), of which, after careful evaluation
of the accompanying questionnaires, 2536 were included
in the study analysis (2536/2595, i.e. 97.7% of original
population). In Table 1, distribution of nasopharyngeal
sampling specimens and isolated strains per geographic
region is shown. Carriage rates differed significantly
among differed regions. In Figure 1, a map of Greece is
provided indicating the geographical location of the sam-
pling sites, with the respective sampling population, car-
riage rates and penicillin resistance rates.
Nasopharyngeal carriage of S pneumoniae strains
A total of 793 pneumococcal strains was isolated in the
study from the original 2595 nasopharyngeal specimens
(mean carriage rate within study period 793/2595 =
30.55%). Of those, 780 isolates survived shipment and
storage and were microbiologically processed, and finally
746 strains were included in the present protocol analysis
of the 2536 properly filled questionnaires (mean carriage
in per protocol analysis 746/2536 = 29.41%). Carriage of
pneumococcal strains was related to age, period and
region of sampling, use of antibiotics in the last trimester
(last month not included) and history of respiratory infec-
tions in the last year. Antibiotic use during the last month
did not affect carriage rates of pneumococci. In Table 2,
analysis of potential risk factors for nasopharyngeal car-
riage of pneumococci, as defined by the protocol ques-
tionnaire, is listed.
Susceptibility testing
In Table 3, results for resistance rates and MIC distribution
parameters for all antibiotics tested are shown per region
of sampling. Resistance rates differed significantly among
different geographic regions. Multiresistant strains formed
23.86% of the carriage isolates (178/746), while com-
bined resistance to penicillin and erythromycin was docu-
mented for 75/746 of the total sample (10.05%). No
resistance to moxifloxacin and levofloxacin was docu-
mented.BMC Infectious Diseases 2009, 9:120 http://www.biomedcentral.com/1471-2334/9/120
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Risk factors for carriage of resistant pneumococci
Recent antibiotic use in the last month-irrespective of
antibiotic class, duration of administration and number
of courses of antibiotics- was strongly associated with the
isolation of resistant pneumococci to a single or multiple
antibiotics. Moreover, increasing number of antibiotic
courses in the last month increased the likelihood of iso-
lating a resistant pneumococcal strain Odds Ratio (OR)
per antibiotic course for penicillin resistance = 1.35, 95%
Confidence Interval (CI) <0.99–1.83> P = 0.05, and OR
for erythromycin resistance = 1.43, CI <1.11–1.83> P =
0.004). Combined resistance to penicillin and erythromy-
cin and multiresistance (3 or more classes of antibiotics)
were also strongly related to antibiotic use in the month
preceding sampling (OR for combined resistance = 2.09,
CI <1.24–3.52> P = 0.002, and OR for multiresistance =
2.02, CI <1.38–2.96> P < 0.001). In terms of non-suscep-
tibility (i.e. intermediate and fully resistant strains
Map of Greece with the geographic location of different regions participating in the 2004 Streptococcus pneumoniae nasopharyn- geal study For every region, the number of children sampled, the respective carriage rates and penicillin resistance rates  (PGR%) are provided in the boxes Figure 1
Map of Greece with the geographic location of different regions participating in the 2004 Streptococcus pneu-
moniae nasopharyngeal study For every region, the number of children sampled, the respective carriage rates 
and penicillin resistance rates (PGR%) are provided in the boxes.
 
 
 
 
 
 
 
Alexandroupolis 
102 children 
33.33% carriage rate 
8.82% PG-R
Ioannina 
59 children 
44.07% carriage rate 
7.69% PG-R
Halkida, Evia 
271 children 
50.92% carriage rate 
15.22% PG-R
Thessaloniki 
650 children 
18.77% carriage rate 
7.38% PG-R
Nafplio-Tripoli-
Sparti, Peloponnese 
426 children 
23.71% carriage rate 
13.86% PG-R 
Athens 
932 children 
29.29% carriage rate 
15.75% PG-R
 
 
 
Heraklion Crete 
96 children 
54.17% carriage rate 
25% PG-R
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together), antibiotic use both in the last month and in the
preceding 3 months (last month excluded) held a statisti-
cally significant correlation with carriage of a penicillin
and/or erythromycin non susceptible strain. For children
that had received an antibiotic course in the last trimester,
the possibility of carrying a resistant (or a non-suscepti-
ble) strain in their nasopharynx was even greater, if they
had additionally received an antibiotic course in the last
month (P < 0.001, OR 4.18 for resistance, 95%CI 2.06–
8.54). In Table 4, risk factors for carriage of a resistant or
non-susceptible strain are listed in full detail. Carriage of
ciprofloxacin resistant strains was independent of antibi-
otic use.
Use of antibiotics and resistance
A significant number of children from the total study pop-
ulation had at least one antibiotic course in the month
preceding sampling (31.03%) or in the previous trimester
(42.43%). Administration of antibiotics did not differ
among geographic regions. The majority of antibiotic
courses in the carriers' group were prescribed by a doctor
either in the preceding month (92.5%) or trimester
(87.8%). The rest of the consumed antibiotics were pur-
Table 1: Distribution of nasopharyngeal samples and carriage rates of pneumococcal strains per geographic region.
City/Prefecture Total Number
of children sampled
Number of pneumococcal
strains isolated
Carriage rate
%
Athens.
Attika
932 273 29.29%
Halkida.
Evia
271 138 50.92%*
Thessaloniki.
Central Macedonia
650 122 18.77%*
Ioannina.
Epirus
59 26 44.07%*
Alexandroupolis.
Thrace
102 34 33.33%
Herakleion.
Crete
96 52 54.17%*
Nafplio-Tripoli-Sparti.
Peloponnese
426 101 23.71%
Greece in total 2536 746 29.42%
* flags statistically significant differences at p level of = 0.05. as compared to Attika prefecture
Table 2: Risk factors for carriage of pneumococcal strain.
Odds Ratio (OR) P 95% CI
Gender (boys) 1.019 0.827 0.855–1.211
Age (<3 years old) 0.886 0.001 0.824–0.953
Private vs. public daycare centre 0.862 0.128 0.712–1.043
Antibiotic consumption
In the last month 0.866 0.139 0.717–1.040
In the last trimester 1.262 0.009 1.060–1.501
Siblings <8 ys in the family (yes or no) 1.036 0.535 0.926–1.159
History of respiratory tract infections 0.745 0.024 0.577–0.962
History of acute otitis media episodes 1.098 0.288 0.923–1.306
Steroid use 1.074 0.525 0.861–1.340
History of hospital admission 0.751 0.296 0.439–1.285
Parents health-care workers 1.176 0.210 0.912–1.517BMC Infectious Diseases 2009, 9:120 http://www.biomedcentral.com/1471-2334/9/120
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chased over the counter by parents' initiative (5.55% and
9.8%) or by pharmacists' advice (1.85% and 2.3% of cases
for the last month and trimester respectively).
The most common infections for prescribing an antibiotic
were similar in rates in both groups (carriers and non-car-
riers). Rates for most common causes were as follows:
acute otitis media 33.56 – 31%, tonsillitis 13.34 – 11%,
lower respiratory tract infections 4.26 – 4%, and virus-
related respiratory tract infections 28.2 – 28% (mostly rhi-
nopharyngitis, tracheobronchitis and laryngitis), respec-
tively for each group. Most commonly prescribed
antibiotics were amoxicillin-clavulanate (35%) and oral
2nd generation cephalosporins (31%), namely cefaclor,
cefprozil and cefuroxime axetil.
Serotype distribution
Among the 380 pneumococcal strains displaying resist-
ance to at least 1 antibiotic class, serotyping was available
for 317 strains (83.5% of resistant strains). The distribu-
tion of serotypes per geographic region and the respective
coverage of the heptavalent pneumococcal conjugate vac-
cine is presented in Table 5. Serotypes 19F, 14, 9V, 23F
and 6B formed 70.6% of the total number of resistant
strains serotyped.
Discussion
The present study is the first surveillance study conducted
in Greece at nation-wide level in the pre-vaccination era,
with representative samples per geographical region,
according to the age-specific population distribution in
the most recent records of the National Registry in March
2001 [12].
Carriage rates in the present study varied significantly with
age, period of sampling and the geographic area visited.
This significant trend differentiation stresses the impor-
tance of sequential sampling in a specific area and multi-
focal sampling at a specific time-point, as useful tools in
the epidemiological studies of resistance. It must be noted
that regional differences in carriage rates did not affect
resistance/nonsusceptibility rates. Resistance rates dif-
fered among different regions. This difference per region
renders the results of a multicenter study even more valu-
able, as it may predict similar trends in the clinical isolates
[13]. In the present study serotyping was performed only
in the resistant strain population. Thus, the association of
specific serotypes with specific resistance patterns cannot
be accurately performed and regional variability in resist-
ance rates for penicillin and erythromycin in relation to
serotype distribution requires caution.
Table 3: Distribution of MIC50/MIC90 values and resistance/nonsusceptibility rates per geographic region
City/Prefecture #
strains
PG CXM CTX ERY COT TET CIP
Athens. %ns-%r 37.9–15.8 29.8–28.7 1.8–0.4 33.2–32.1 43.6–26 24.2–23.4 3.8
Attika 273 MIC50/MIC90 0.023–2 0.047–4 0.023–0.75 0.125–256 0.5–32 0.125–24 0.75–1.5
Halkida. %ns-%r 37–15.2 23.9–21.7 1.4–0 39.1–37.7 51.8–29.2 34.8–30.4 3.8
Evia 138 MIC50/MIC90 0.023–2 0.032–3 0.023–0.75 0.125–256 0.75–32 0.19–32 0.75–2
Thessaloniki. %ns-%r 32.8–7.4* 21.3–18 0.8–0 34.2–34.2 38–29.8 21.3–20.5 3.3
Central Macedonia 122 MIC50/MIC90 0.032–1 0.032–2 0.016–0.5 0.125–24 0.5–32 0.25–48 0.75–1.5
Ioannina. %ns-%r 19.2*-7.7* 11.5–11.5 2.9–0 42.3–38.5 42.3–19.2 19.2–19.2 0
Epirus 26 MIC50/MIC90 0.032–1 0.047–3 0.023–0.38 0.25–96 0.5–18 0.125–24 0.5–1
Alexandroupolis. %ns-%r 11.8*-8.8* 8.8–8.8 0–0 17.6*-17.6 35.3–2.9 14.7–11.8 11.8
Thrace 34 MIC50/MIC90 0.023–1 0.023–2 0.023–0.5 0.125–2.5 0.38–2 0.125–24 1–3
Herakleion. %ns-%r 53.8*-25.5* 40.4–34.6 0–0 66.7*-66.7 65.4–26.9 48.1–46.2 6.1
Crete 52 MIC50/MIC90 0.12–2 0.5–6 0.12–0.75 32–256 1–32 1.5–96 0.75–1.5
Nafplio-Tripoli-Sparti. %ns-%r 28.0*-14.0* 24.0–24.0 1.0–0.0 14.0*-14.0 30.0–20.0 21.0–21.0 2.0
Peloponnese 101 MIC50/MIC90 0.023–2 0.023–2 0.023–0.75 0.094–128 1–2 0.125–24 0.75–2
Greece in total 746 %ns-%r 34.8–14.1 25.7–23.9 1.3–0.1 33.8–33 43.8–25.2 26.3–24.8 4.0
MIC50/MIC90 0.023–1.5 0.032–3 0.023–0.75 0.125–256 0.5–32 0.125–24 0.75–2
No resistance was recorded for levo- and moxi-floxacin. Respective MIC50/90 values were 0.75–1 and 0.125–0.19 mg/L
PG: penicillin. CXM: cefuroxime. CTX: ceftriaxone. ERY: erythromycin. COT: cotrimoxazole. TET: tetracycline. CIP: ciprofloxacin
*flags statistically significant differences at p level of = 0.05 when compared to Attika regionBMC Infectious Diseases 2009, 9:120 http://www.biomedcentral.com/1471-2334/9/120
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Table 4: Risk factors for carriage of a resistant or a non-susceptible pneumococcal strain to penicillin and to erythromycin
Univariate analysis Multivariate analysis
OR 95%CI P OR 95%CI P
Penicillin resistance
Male gender 0.75 0.49–1.15 0.196 0.76 0.48–1.19 0.244
Age <3 years old 0.79 0.66–0.94 0.009 0.76 0.70–1.06 0.164
Sampling period* 0.48 0.31–0.73 0.001 0.57 0.36–0.92 0.023
Antibiotic use in the last month 1.94 1.26–2.98 0.002 2.00 1.26–3.17 0.003
Antibiotic use in the last trimester 1.07 0.70–1.63 0.749 1.09 0.69–1.71 0.696
History of acute otitis media episodes 1.07 0.70–1.63 0.749 0.90 0.54–1.51 0.709
History of respiratory tract infections 0.89 0.50–1.58 0.652 0.96 0.48–1.92 0.928
Other sibling(s) in the household <8 years old 0.96 0.62–1.47 0.814 1.07 0.67–1.71 0.751
Steroid use 1.02 0.64–1.59 0.971 1.20 0.715–2.02 0.486
Admission to the hospital in the last year 2.40 0.83–6.87 0.159 2.57 0.72–9.18 0.145
Prefecture of Thessaloniki** 0.42 0.19–0.9 0.026 0.33 0.13–0.83 0.019
Prefecture of Evia(Halkida)** 1.11 0.66–0.87 0.685 0.91 0.43–1.94 0.825
Prefecture of Evros(Alexandroupolis)** 0.57 0.17–1.92 0.458 0.52 0.14–1.91 0.328
Prefecture of Epirus(Ioannina)** 0.49 0.11–2.13 0.564 0.20 0.01–1.30 0.635
Prefecture of Peloponnese** 0.98 0.53–1.81 1.000 1.09 0.52–2.29 0.803
Prefecture of Herakleion, Crete** 2.17 1.11–4.22 0.036 1.69 0.70–4.07 0.238
Erythromycin resistance
Male gender 1.06 0.78–1.45 0.693 1.00 0.72–1.39 0.958
Age <3 years old 0.82 0.72–0.94 0.005 0.866 0.74–1.00 0.061
Sampling period* 0.46 0.33–0.63 < 0.001 0.52 0.37–0.73 < 0.001
Antibiotic use in the last month 1.43 1.04–1.96 0.025 1.92 1.35–2.72 < 0.001
Antibiotic use in the last trimester 1.19 0.87–1.63 0.266 1.30 0.94–1.80 0.112
History of acute otitis media episodes 1.39 1.02–1.90 0.034 1.13 0.78–1.64 0.508
History of respiratory tract infections 0.78 0.50–1.20 0.262 0.57 0.34–0.95 0.031
Other sibling(s) in the household <8 years old 0.93 0.68–1.28 0.686 0.89 0.63–1.26 0.534
Steroid use 1.33 0.96–1.84 0.081 1.20 0.81–1.77 0.356
Admission to the hospital in the last year 0.77 0.27–2.19 0.801 0.87 0.23–3.23 0.846
Prefecture of Thessaloniki** 1.06 0.70–1.61 0.752 0.99 0.56–1.75 0.993
Prefecture of Evia(Halkida)** 1.29 0.87–1.89 0.194 1.03 0.59–1.78 0.913
Prefecture of Evros(Alexandroupolis)** 0.42 0.17–1.03 0.061 0.50 0.19–1.32 0.165
Prefecture of Epirus(Ioannina)** 1.28 0.57–2.86 0.531 1.39 0.51–3.80 0.516
Prefecture of Peloponnese** 0.36 0.36–0.97 0.017 0.41 0.21–0.81 0.010
Prefecture of Herakleion, Crete** 4.22 2.24–7.98 < 0.001 3.26 1.55–6.84 0.002
Penicillin nonsusceptibility
Male gender 0.89 0.79–1.47 0.638 0.89 0.65–1.23 0.499
Age <3 years old 0.78 0.68–0.89 < 0.001 0.82 0.71–0.96 0.013
Sampling period* 0.5 0.37–0.69 < 0.001 0.58 0.42–0.82 0.002
Antibiotic use in the last month 1.71 1.23–2.38 0.001 1.66 1.17–2.35 0.004
Antibiotic use in the last trimester 1.36 1.00–1.84 0.045 1.48 1.07–2.04 0.017
History of acute otitis media episodes 1.04 0.77–1.41 0.815 0.82 0.56–1.18 0.297
History of respiratory tract infections 1.06 0.68–1.65 0.825 1.13 0.68–1.89 0.624
Other sibling(s) in the household <8 years old 0.84 0.61–1.28 0.686 0.85 0.61–1.20 0.379
Steroid use 1.30 0.95–1.79 0.102 1.36 0.93–2.01 0.108
Admission to the hospital in the last year 1.52 0.59–3.91 0.453 1.97 0.61–6.32 0.251
Prefecture of Thessaloniki** 0.89 0.59–1.35 0.678 0.48 0.27–0.86 0.014
Prefecture of Evia(Halkida)** 1.12 0.76–1.64 0.554 0.73 0.42–1.26 0.265
Prefecture of Evros(Alexandroupolis)** 0.21 0.074–0.63 0.005 0.19 0.06–0.57 0.003
Prefecture of Epirus(Ioannina)** 0.43 0.16–1.16 0.098 0.17 0.03–0.81 0.026
Prefecture of Peloponnese** 0.69 0.43–1.10 0.143 0.70 0.40–1.22 0.215
Prefecture of Herakleion, Crete** 1.91 1.05–3.48 0.003 1.39 0.68–2.62 0.357
Erythromycin nonsusceptibility
Male gender 1.08 0.79–1.47 0.638 1.02 0.74–1.41 0.881
Age <3 years old 0.8 0.7–0.92 0.002 0.84 0.72–0.97 0.023
Sampling period* 0.46 0.34–0.64 < 0.001 0.53 0.37–0.74 < 0.001BMC Infectious Diseases 2009, 9:120 http://www.biomedcentral.com/1471-2334/9/120
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One of the risk factors amenable to intervention for carry-
ing a resistant or a non-susceptible pneumococcal strain
in the nasopharynx for a healthy preschool child was the
use of antibiotics in the month preceding sampling. Addi-
tionally, antibiotic use was related to the isolation of com-
bined penicillin-erythromycin resistant, as well as
multiresistant pneumococcal strains Numerous studies
[14-16] have pointed out antibiotic consumption as a
very strong pressure factor for the development of resist-
ance, irrespective of ecological setting (individuals-com-
munity). Chung et al [17] have recently shown that
prescription of amoxicillin doubled the risk of recovery of
β lactamase producing Haemophilus influenzae strains.
Although this effect was transitory at an individual level (2
weeks), it was sufficient to sustain a high level of antibi-
otic resistance in the study population.
Acute otitis media was the most frequent infection for
which a child received antibiotics in our study. Nonethe-
less, a similar proportion of children (approx. 30%) con-
sumed antibiotics for infections which seemed to be of
viral cause by all descriptions in the questionnaire used. It
must be stressed that acute otitis media does not always
require prompt administration of antibiotics, as it may be
of viral origin in certain cases. In Finland Palmu et al
recorded negative cultures of middle ear fluid in approxi-
mately 35% of children with acute otitis media in 2004
[18]. Moreover, a wait-and-see approach to acute otitis
media treatment in the paediatric population seems to
reduce antibiotic consumption and subsequent resistance
without jeopardizing children's safety and well-being
[19].
Antibiotic use in the last month 1.81 1.3–2.52 < 0.001 1.86 1.31–2.64 < 0.001
Antibiotic use in the last trimester 1.44 1.05–1.97 0.021 1.32 0.95–1.82 0.091
History of acute otitis media episodes 1.44 1.06–1.96 0.019 1.16 0.80–1.67 0.426
History of respiratory tract infections 0.77 0.50–1.19 0.263 0.65 0.34–0.94 0.028
Other sibling(s) in the household <8 years old 0.97 0.71–1.33 0.873 0.92 0.65–1.30 0.662
Steroid use 1.26 0.91–1.73 0.610 1.13 0.77–1.67 0.519
Admission to the hospital in the last year 0.74 0.26–2.11 0.802 0.86 0.23–3.17 0.820
Prefecture of Thessaloniki** 1.02 0.67–1.54 0.916 0.92 0.52–1.62 0.794
Prefecture of Evia(Halkida)** 1.33 0.90–1.95 0.162 1.12 0.65–1.94 0.671
Prefecture of Evros(Alexandroupolis)** 0.40 0.16–0.99 0.042 0.46 0.17–1.21 0.120
Prefecture of Epirus(Ioannina)** 1.45 0.65–3.22 0.399 1.59 0.60–4.25 0.347
Prefecture of Peloponnese** 0.34 0.12–0.92 0.002 0.38 0.2–0.75 0.005
Prefecture of Herakleion, Crete** 4.02 2.13–7.58 < 0.001 3.39 1.61–7.17 0.005
* reference category for period of sampling: February
** reference category for prefecture of sampling: Athens, prefecture of Attika
Table 4: Risk factors for carriage of a resistant or a non-susceptible pneumococcal strain to penicillin and to erythromycin (Continued)
Table 5: Serotype distribution among pneumococcal strains displaying resistance to at least one antibiotic class (n = number of strains, 
% = percent of strains per geographic region).
Athens
(n, %)
Halkida
(n, %)
Thessaloniki
(n, %)
Ioannina
(n, %)
Alexandroupolis
(n, %)
Herakleion
(n, %)
Peloponnese
(n, %)
Total
(n,%)
PCV7* serotypes 80 (70.17) 42 (73.68) 33 (58.92) 10 (76.92) 6 (54.55) 25 (75.76) 30 (90.91) 226 (71.29)
19F 32 (28.07) 20 (35.09) 9 (16,07) 2 (15.38) 3 (27.27) 11 (33.33) 10 (30.3) 87 (27.44)
14 10 (8.77) 6 (10.53) 10 (17.86) 11 (33.33) 3 (9.09) 40 (12.62)
9V 20 (17.54) 2 (3.57) 2 (15.38) 10 (30.3) 34 (10.73)
23F 10 (8.77) 6 (10.53) 6 (10.71) 5 (38.46) 1 (9.09) 1 (3.04) 4 (12.13) 33 (10.41)
6B 8 (7.02) 10 (17.54) 5 (8.93) 1 (7.69) 2 (18.18) 2 (6.06) 2 (6.06) 30 (9.46)
18C 1 (1.79) 1 (3.03) 2 (0.63)
PCV7-related serotypes 17 (14.92) 10 (17.55) 11 (19.66) 0 2 (18.18) 4 (12.12) 0 43 (13.56)
6A 7 (6.14) 3 (5.26) 5 (8.93) 0 2 (6.06) 17 (5.36)
Other related 10 (8.78) 7 (12.29) 6 (10.73) 2 (18.18) 2 (6.06) 26 (8,20))
Non PCV7 serogroups 10 (8.77) 3 (5.26) 8 (14.28) 3 (23.08) 1 (9.09) 2 (6.06) 3 (9.09) 32 (10.1)
Nontypeable strains 7 (6.14) 2 (3.51) 4 (7.14) 0 2 (18.18) 2 (6.06) 0 16 (5.05)
Total 114 (100) 57 (100) 56 (100) 13 (100) 11 (100) 33 (100) 33 (100) 317 (100)
*PCV7: heptavalent pneumococcal conjugate vaccineBMC Infectious Diseases 2009, 9:120 http://www.biomedcentral.com/1471-2334/9/120
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Approximately 90% of the prescriptions originated from
practicing physicians in the community, while in the
remaining 10% of cases, parents had access to antibiotics
without doctor's prescription, although this is not abiding
by antibiotics policy law [20]. As demonstrated by Guille-
mot et al [21], intensive educational strategies, targeting to
optimize antibiotic use both in terms of indications and
of dose/duration of administration, significantly reduced
the colonization with penicillin non-susceptible pneumo-
cocci in areas with high prevalence of resistance.
The heptavalent pneumococcal vaccination (PCV7) cov-
ered 71.32% of resistant strains in total in the present
study. The most prevalent serotypes in our population car-
ried the heavier burden of antibiotic resistance. Imple-
mentation of the heptavalent vaccine has been shown to
be highly efficacious in decreasing the incidence of vac-
cine-type antibiotic-resistant strains in disease and coloni-
zation [5]. A study by Grivea et al[8], at a regional level in
Thessaly, Central Greece between 2005–2007, showed
that increasing rates of PCV7 population coverage was
associated with a reduction in colonization by PCV7-
related serotypes in vaccinated (from 33% to 8.6%, P <
0.001) and unvaccinated children (from 36% to 17%, P =
0.05). Moreover, a decrease in the rate of highly penicillin
resistant pneumococcal isolates was recorded only in vac-
cinated children (from 11% to 0.6%, P = 0.001), whereas
rates for penicillin intermediate strains were not affected.
In a community setting of high antibiotic consumption,
Frazao et al[22] showed that PCV7 vaccination was suc-
cessful in the reduction of vaccine related strains, but it
did not change the frequency of nasopharyngeal carriage
of drug resistant pneumococci, implying the crucial role
of antibiotic consumption on the serotype replacement
phenomenon by drug-resistant non-vaccine related pneu-
mococcal strains.
To reduce antibiotic resistance in the community, reduc-
ing unnecessary antibiotic prescriptions combined with
the implementation of the heptavalent conjugate pneu-
mococcal vaccine are probably two of the most efficient
strategies. In a large scale prospective study in France from
2001 to 2005 in children presenting with acute otitis
media, Cohen et al [23] showed that unvaccinated chil-
dren who had received antibiotics within the last three
months had a 4-fold greater risk of carrying a penicillin
resistant strain than vaccinated children who had not
received antibiotics. Moreover, vaccination reduced the
antibiotic consumption from 51.6% to 38.5%, as well as
the risk for a child to carry a penicillin resistant pneumo-
coccal strain from 15% to 3%.
Conclusion
Colonization with a pneumococcal strain is a usual event
in the everyday life of preschool children. Epidemiologi-
cal data derived from the present surveillance study stress
the importance of recent antibiotic use in the colonization
of otherwise healthy children's nasopharynx by resistant
strains of S pneumoniae. The heptavalent pneumococcal
conjugate vaccine, as shown from the serotype distribu-
tion in the pre-vaccination era, could provide coverage
against the majority of resistant strains. In settings with a
high antibiotic consumption profile in the community,
like the one described in the present study, prudent use of
antibiotics at an individual level coupled with vaccination
could prove helpful in decreasing pneumococcal resist-
ance rates in the community, thus facilitating treatment of
pneumococcal infection.
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